What Is Ibutamoren Mesylate Same as MK-677? (Mechanism

What Is Ibutamoren Mesylate Same as MK-677? (Mechanism Explained)

Research published in the Journal of Clinical Endocrinology & Metabolism found that ibutamoren increased mean serum growth hormone levels by 97% after a single 25mg dose. But here's what most researchers miss: the compound tested under the name 'MK-677' in that trial is chemically identical to ibutamoren mesylate. They're not similar compounds or related molecules. They're the exact same substance with two names used interchangeably across clinical literature.

Our team has worked with researchers across hundreds of peptide studies. The confusion around ibutamoren mesylate vs MK-677 creates sourcing errors, dosing miscalculations, and literature review gaps that compromise study design. This isn't a trivial naming issue. Understanding the equivalence matters for procurement, protocol accuracy, and interpreting decades of published data that uses both terms without clarification.

What is ibutamoren mesylate, and is it the same as MK-677?

Ibutamoren mesylate and MK-677 are the same compound. A non-peptide growth hormone secretagogue that stimulates pulsatile GH release by mimicking ghrelin at the GHSR-1a receptor. 'Ibutamoren' is the International Nonproprietary Name (INN); 'MK-677' is the Merck research code from its development phase; 'mesylate' specifies the methanesulfonate salt form used for stability and solubility. All three terms refer to identical molecular structure (C27H36N4O5S) with the same mechanism, bioavailability, and half-life.

The naming confusion stems from clinical trial indexing. Early-phase studies published by Merck Research Laboratories used 'MK-677' exclusively, while later Phase II and III trials. Conducted after the compound received its INN designation. Listed it as 'ibutamoren' or 'ibutamoren mesylate.' PubMed abstracts for the same compound now appear under both names, creating the false impression of two separate agents. This article clarifies the equivalence, explains why both names persist, and covers dosing implications, sourcing verification, and literature search strategy for researchers working with this growth hormone secretagogue.

The Chemical Identity: Why Two Names Describe One Molecule

Ibutamoren mesylate and MK-677 are chemically identical because 'MK-677' is the internal research designation Merck assigned during preclinical development, while 'ibutamoren mesylate' is the standardised pharmaceutical name adopted post-development. The active compound in both is ibutamoren. A spiropiperidine derivative that binds to the growth hormone secretagogue receptor (GHSR-1a) with nanomolar affinity. The 'mesylate' suffix indicates the salt form: ibutamoren base combined with methanesulfonic acid to improve aqueous solubility and powder stability during storage.

Here's what we've found working with researchers who source this compound: suppliers list it under both names, and some labs mistakenly order both thinking they're acquiring chemically distinct molecules. They're not. The molecular formula (C27H36N4O5S), CAS registry number (159752-10-0 for the mesylate salt), and receptor binding profile are identical regardless of which name appears on the certificate of analysis. The only nomenclature difference that matters is whether you're purchasing the mesylate salt (standard for research) versus the free base (uncommon and less stable). Both names. Ibutamoren mesylate and MK-677. Refer to the mesylate salt unless explicitly stated otherwise.

How Ibutamoren Mesylate (MK-677) Works: Mechanism of Action

Ibutamoren mesylate functions as a ghrelin mimetic, binding to the GHSR-1a receptor in the anterior pituitary and hypothalamus to trigger growth hormone release without suppressing endogenous GH production. Unlike exogenous GH administration, which shuts down the body's natural pulsatile secretion, ibutamoren mesylate preserves the physiological GH pulse amplitude and frequency. It amplifies existing pulses rather than replacing them. This distinction is critical: studies show sustained ibutamoren use maintains normal feedback loops, whereas synthetic GH causes receptor downregulation and post-treatment suppression.

The compound also elevates IGF-1 (insulin-like growth factor 1) levels as a downstream consequence of increased GH secretion. A 2-year clinical trial published in the Annals of Internal Medicine found that 25mg daily ibutamoren mesylate increased serum IGF-1 levels by 46% from baseline after 12 months, with sustained elevation throughout the study period. The mechanism differs from direct IGF-1 administration: ibutamoren-driven IGF-1 elevation occurs through hepatic synthesis in response to elevated GH, maintaining normal IGF-binding protein ratios and avoiding the supraphysiological spikes that characterise exogenous IGF-1 dosing.

Our experience with research applications shows the selectivity of ibutamoren mesylate for GHSR-1a is what prevents the cortisol elevation and prolactin surges seen with earlier secretagogues like GHRP-6. Receptor binding studies demonstrate >1000-fold selectivity for GHSR-1a over other ghrelin receptor subtypes, which translates to a cleaner pharmacological profile with fewer off-target endocrine effects during extended administration.

MK-677 vs Ibutamoren: Comparison Across Research Applications

The only naming context where the distinction matters is regulatory and procurement paperwork. When ordering from synthesis labs, specifying 'ibutamoren mesylate' ensures you receive the mesylate salt (standard research form), whereas 'MK-677' alone may require clarification. Certificates of analysis should list both names and confirm the mesylate salt form. If a supplier uses 'MK-677' but the CoA lists a different CAS number, that's a red flag. The compound may be mislabeled or adulterated.

What If: Ibutamoren Mesylate Research Scenarios

What If I Find Studies Listed Under MK-677 and Others Under Ibutamoren — Are They Comparable?

Yes. Directly comparable. Both names describe the same molecular entity, so pharmacokinetic data, dosing ranges, and efficacy outcomes from MK-677 trials apply to ibutamoren mesylate protocols without adjustment. The naming split reflects publication timeline: early trials (1995–2000) used the research code MK-677, while post-2000 studies adopted the INN designation 'ibutamoren.' Merging both search terms in your literature review captures the complete evidence base, including pivotal Phase II trials published under MK-677 and later long-term safety data indexed as ibutamoren.

What If My Supplier Lists 'Ibutamoren' Without the Mesylate Designation — Is It the Same Compound?

Not necessarily. Verify the salt form. 'Ibutamoren' without 'mesylate' could indicate the free base form, which has lower aqueous solubility and different stability characteristics than the mesylate salt used in clinical trials. Request a certificate of analysis listing the CAS number (159752-10-0 for mesylate) and molecular weight (624.8 g/mol for the mesylate salt versus 528.7 g/mol for free base). Most research-grade suppliers provide ibutamoren mesylate by default, but confirmation prevents dosing errors caused by unintentional free base procurement.

What If I'm Designing a Protocol Based on MK-677 Data — Do I Adjust Dosing for Ibutamoren Mesylate?

No adjustment needed. Use the same dosing. Clinical trials testing 'MK-677' at 10mg, 25mg, or 50mg daily used ibutamoren mesylate as the administered compound. The research code and INN refer to identical formulations with identical bioavailability, so a protocol citing '25mg MK-677 daily' translates directly to '25mg ibutamoren mesylate daily' without recalculation. The only scenario requiring dose conversion is if you're working with the free base form, which has 18% lower molecular weight. But that's uncommon in research settings.

The Unvarnished Truth About Ibutamoren Mesylate and MK-677

Here's the honest answer: there is no pharmacological difference between ibutamoren mesylate and MK-677. None. The persistence of two names in research literature and supplier catalogs creates confusion that doesn't reflect any underlying chemical distinction. Researchers waste time cross-referencing studies, labs order duplicate compounds thinking they're acquiring alternatives, and procurement teams flag 'discrepancies' between purchase orders listing MK-677 and invoices listing ibutamoren mesylate. All of it stems from nomenclature convention, not molecular reality.

The name you use matters for one reason only: literature search completeness. PubMed indexes early trials under MK-677 and later trials under ibutamoren, so searching only one term omits half the published data. Beyond that, the names are functionally interchangeable. Same molecule, same receptor target, same dosing, same stability profile, same everything. If a supplier charges different prices for 'MK-677' versus 'ibutamoren mesylate,' you're seeing a markup based on naming confusion, not product differentiation.

Verification and Sourcing: Ensuring Compound Identity

Authenticity verification for ibutamoren mesylate requires three-point confirmation: CAS number match (159752-10-0), molecular weight confirmation (624.8 g/mol for mesylate salt), and HPLC purity analysis showing ≥98% single-peak purity. Certificates of analysis should list both 'ibutamoren mesylate' and 'MK-677' in the compound name field. Reputable synthesis labs acknowledge the naming equivalence explicitly to prevent ordering errors. If the CoA lists only one name and a different CAS number, request clarification before proceeding.

Our team's experience across peptide sourcing shows that third-party verification through independent mass spectrometry is the gold standard when working with high-value studies. Some suppliers provide in-house CoAs that list correct nomenclature but deliver lower-purity product than specified. Sending a sample to an independent analytical lab for MS/MS fragmentation analysis confirms both identity and purity independent of supplier documentation. For ibutamoren mesylate, the expected base peak in positive-ion mode ESI-MS is m/z 529 [M+H]+ (free base) or m/z 625 [M+H]+ (mesylate salt). Fragmentation patterns inconsistent with these values indicate adulteration or mislabeling.

When working with compounds indexed under multiple names, cross-reference your procurement documentation against published trial formulations. The 2-year Annals of Internal Medicine trial administered '25mg oral ibutamoren mesylate daily'. If your protocol cites that study, your certificate of analysis should confirm mesylate salt form and list dosing in milligrams of the mesylate, not free base equivalent. Dosing discrepancies between research code and INN-indexed studies don't exist for ibutamoren mesylate because all published trials used the mesylate formulation, but verifying this prevents errors if sourcing from labs unfamiliar with the compound's clinical history.

If the research objective involves replicating published MK-677 protocols, the sourced compound must match the exact salt form and purity grade used in those trials. Clinical-grade ibutamoren mesylate used in Phase III studies underwent USP-grade synthesis with ≥99% purity. Research applications aiming for direct comparability should specify the same standard. Lower-purity analogs (95–98%) are acceptable for preliminary studies but introduce variables that complicate direct comparison with published efficacy data. Knowing that ibutamoren mesylate and MK-677 are the same compound means knowing that any purity, formulation, or sourcing decision applies equally regardless of which name appears in your literature references or purchase orders.

FAQs

[
{
"question": "Is ibutamoren mesylate the same as MK-677, or are they different compounds?",
"answer": "Ibutamoren mesylate and MK-677 are the same compound. 'MK-677' is the Merck research designation from its development phase, while 'ibutamoren mesylate' is the International Nonproprietary Name (INN) with the salt form specified. Both refer to the identical molecular structure (C27H36N4O5S), the same GHSR-1a receptor mechanism, and the same pharmacokinetic profile. The naming difference reflects publication timeline and regulatory convention, not chemical distinction."
},
{
"question": "Why do some studies use MK-677 and others use ibutamoren if they're the same thing?",
"answer": "Early-phase clinical trials (1995–2000) conducted by Merck Research Laboratories used the internal research code 'MK-677,' while later trials adopted the INN designation 'ibutamoren' or 'ibutamoren mesylate' after the compound received formal nomenclature approval. PubMed and other databases index studies under whichever name was used in the original publication, creating the appearance of two separate agents when searching literature. Comprehensive evidence reviews require querying both terms to capture the full dataset."
},
{
"question": "What does 'mesylate' mean in ibutamoren mesylate, and does MK-677 contain it?",
"answer": "'Mesylate' indicates the methanesulfonate salt form. Ibutamoren base combined with methanesulfonic acid to improve aqueous solubility and chemical stability during storage. MK-677, as used in clinical trials, refers to the same mesylate salt formulation unless explicitly stated as the free base. The mesylate form is the standard research-grade version with a molecular weight of 624.8 g/mol, while the free base (rarely used) weighs 528.7 g/mol. Both names default to the mesylate salt in research contexts."
},
{
"question": "Do I need to adjust dosing if a protocol lists MK-677 but I'm using ibutamoren mesylate?",
"answer": "No adjustment is needed. The dosing is identical. Clinical trials published under 'MK-677' used ibutamoren mesylate as the administered compound, so a protocol specifying '25mg MK-677 daily' translates directly to '25mg ibutamoren mesylate daily' with no recalculation. The only scenario requiring conversion is if you're using the free base form instead of the mesylate salt, but free base ibutamoren is uncommon in research-grade sourcing and typically specified explicitly on certificates of analysis."
},
{
"question": "How can I verify that my supplier is providing authentic ibutamoren mesylate and not a different compound labeled as MK-677?",
"answer": "Verify the CAS registry number (159752-10-0 for ibutamoren mesylate), molecular weight (624.8 g/mol for the mesylate salt), and request HPLC purity analysis showing ≥98% single-peak purity. Certificates of analysis from reputable labs list both 'ibutamoren mesylate' and 'MK-677' as synonyms and confirm the salt form explicitly. For high-value studies, third-party mass spectrometry provides independent confirmation. Expect m/z 625 [M+H]+ in positive-ion ESI-MS for the mesylate salt."
},
{
"question": "Is MK-677 FDA-approved, or is only ibutamoren mesylate approved?",
"answer": "Neither MK-677 nor ibutamoren mesylate is FDA-approved for clinical use as of 2026. The compound completed multiple Phase II trials for growth hormone deficiency, sarcopenia, and frailty but was not advanced to Phase III registration trials for any indication. Both names refer to the same investigational agent available for research purposes through licensed peptide suppliers. References to 'MK-677' or 'ibutamoren' in clinical contexts describe research use, not approved therapeutic applications."
},
{
"question": "What is the half-life of ibutamoren mesylate, and is it different from MK-677's half-life?",
"answer": "The half-life is 4–6 hours for both ibutamoren mesylate and MK-677 because they are the same compound. Despite the short plasma half-life, the GH-elevating effect persists for 24 hours due to sustained GHSR-1a activation and pulsatile GH release throughout the dosing interval. This allows once-daily oral administration to maintain therapeutic GH elevation, as demonstrated in clinical trials using both naming conventions."
},
{
"question": "Can I search PubMed for 'MK-677' and find all ibutamoren mesylate studies, or do I need to search both terms?",
"answer": "You must search both terms to capture the complete evidence base. PubMed indexes studies under the name used in the original publication. Early trials are indexed as 'MK-677,' later trials as 'ibutamoren' or 'ibutamoren mesylate,' and some appear under both. A search for 'MK-677 OR ibutamoren' retrieves the full dataset spanning 1995–2026. Relying on a single term omits critical studies, particularly long-term safety data published under the INN designation."
},
{
"question": "Does ibutamoren mesylate have the same receptor selectivity as MK-677?",
"answer": "Yes. Both names describe a compound with >1000-fold selectivity for the GHSR-1a receptor over other ghrelin receptor subtypes. This selectivity profile is intrinsic to the molecular structure and does not vary based on nomenclature. The high receptor selectivity is what differentiates ibutamoren mesylate (MK-677) from earlier growth hormone secretagogues that caused cortisol elevation and prolactin surges due to off-target binding."
},
{
"question": "If I cite MK-677 studies in a research protocol, do I need to clarify that I'm using ibutamoren mesylate?",
"answer": "It's advisable to state the equivalence explicitly to prevent reviewer confusion. Write 'ibutamoren mesylate (also known as MK-677)' on first mention, then use either name consistently throughout the protocol. This clarifies that studies indexed under 'MK-677' inform your ibutamoren mesylate dosing rationale and that no compound substitution or analog is involved. Regulatory and institutional review boards appreciate nomenclature transparency when the same compound appears under multiple names in published literature."
}
]

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

1. Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
2. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
3. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
4. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
5. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
6. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
7. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001